PCT-59: CLINICAL EVALUATION OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA TREATED WITH THE NUTRITIONAL SUPPLEMENT CALPROST

J Pharm Pharmacogn Res 3(suppl. 1): S151, 2015

Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015  September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.

Poster

PCT-59: CLINICAL EVALUATION OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA TREATED WITH THE NUTRITIONAL SUPPLEMENT CALPROST

Jiménez D1, Festary T1, Machado M2, Suarez M2, Silveira D3, Wong H3, Barroso E4, Fernández R4, García I1, Tuero A5, Delgado R1.

1Center for Pharmaceutical Research and Drug Development (CIDEM), Havana, Cuba. E-mail: daise.jimenez@cidem.sld.cu
2Dr Luis Díaz Soto” Clinical Surgical Hospital, Havana, Cuba.
3“Joaquín Albarrán” Clinical Surgical Hospital, Havana, Cuba.
4“Iván Portuondo” Clinical Surgical Hospital, San Antonio de los Baños, Artemisa, Cuba.
5Center for Genetic Engineering and Biotechnology, Havana, Cuba.

 

Introduction: Benign prostatic hyperplasia (BPH) is a common disease in over 50 years-old men. Objective: To evaluate the effect and safety of Calprost (microencapsulated lipophilic extract of pumpkin seed oil) in patients with BPH. Material and Methods: A multicenter, randomized, controlled, open exploratory study was conducted. A total of 131 patients diagnosed with BPH and lower urinary tract symptoms (LUTS) from “Dr. Luis Díaz Soto Hospital”, Joaquín Albarrán” Hospital and “Iván Portuondo” Hospital were included. Two experimental groups, study group (G1-Calprost) (N=81), and control group (G2-terazosin) (N=50) were formed. Efficacy was evaluated through assessing prostate symptom, symptoms urinals, quality of life (IPSS); residual volume (RV) and prostate volume (PV). Safety evaluation included the registration of adverse events (AE) presented together with their intensity, severity and causality. Results: It was found that treatment during three months with Calprost 140 mg capsules had a similar therapeutic effect compared with conventional treatment terazosin 2 mg. There was a significant improvement (p=0.000) in the prostate symptoms score (IPSS) for both groups. Most of the obstructive and irritative urinary symptoms (intermittency, weak stream, frequency and urgency) decreased more markedly in the Calprost group. Meanwhile, in the terazosin group only the nocturia was reduced. At the end of treatment, most of the patients in the study group were classified as pleased quality of life (44.4%); Terazosin-treated patients were mostly classified as Mixed (46%). Median RV (p=0.048) and median VP (p=0.002) decreased significantly in the Calprost group. Most of the AE were recorded the terazosin group (79.4%). Conclusions: The supplement Calprost was probed as a successful treatment of patients with BPH/LUTS, being also well-tolerated.

 

Citation Format: Jiménez D, Festary T, Machado M, Suarez M, Silveira D, Wong H, Barroso E, Fernández R, García I, Tuero A, Delgado R (2015) Clinical evaluation of patients with benign prostatic hyperplasia treated with the nutritional supplement Calprost. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S151. Abstract nr PCT-59.